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This multicentre, double-blind, randomised, placebo-controlled, crossover study aimed to determine the
dose-response of the long-acting muscarinic antagonist (LAMA) glycopyrronium bromide (GB) when
added to beclometasone dipropionate plus formoterol fumarate (BDP/FF) in patients with COPD.
Patients received extraﬁne GB 12.5, 25 or 50 mg twice daily (BID) or placebo for 7 days via pressurised
metered dose inhaler (pMDI), and extraﬁne BDP/FF via pMDI throughout the study. The primary
objective was to demonstrate superiority of GB plus BDP/FF versus BDP/FF in terms of FEV1 area under
the curve from 0 to 12 h (AUC0e12h) on Day 7. Secondary endpoints included: FEV1 AUC0e12h on Day 1;
peak FEV1 and FVC on Days 1 and 7; and trough (12 h post-dose) FEV1, FVC and inspiratory capacity (IC)
on Days 1 and 7.
Of 178 patients randomised (mean age 62.7 years, post-bronchodilator FEV1 48.9%), 172 (96.6%)
completed. Mean FEV1 AUC0e12h on Day 7 was signiﬁcantly higher (p < 0.001) for all GB doses plus BDP/
FF compared to BDP/FF alone, with the difference for the 25 and 50 mg BID doses being clinically relevant
(i.e., 100 mL). The results for the other spirometry endpoints were consistent with the primary
endpoint. Adverse events were reported in 7.4, 5.7 and 8.0% of patients receiving GB 12.5, 25 and 50 mg
BID, respectively, versus 11.0% of patients receiving BDP/FF alone.
This study conﬁrms the value of adding GB to BDP/FF to improve lung function in COPD patients. The
dose of extraﬁne GB 25 mg BID was associated with the best efﬁcacy/safety proﬁle.
Trial registered at: ClinicalTrials.gov.
Registration number: NCT01476813.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Chronic obstructive pulmonary disease (COPD) is characterisedLtd. This is an open access article uby persistent airﬂow limitation, with bronchodilators (particularly
long-acting) being central to disease management [1]. There are
two classes of inhaled long-acting bronchodilators: b2-agonists
(LABAs) and muscarinic antagonists (LAMAs). Long-acting bron-
chodilators improve lung function, alleviate symptoms, increase
exercise performance and reduce exacerbation rates [1,2], and are
recommended for use in patients who are symptomatic despitender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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(ICSs) are used in combination with LABAs in those patients who
are at increased risk of exacerbations [1], and such ICS/LABA
combinations have been shown to reduce the rate of exacerbations
and improve a range of clinically-relevant outcomes compared
with ICS or LABA monotherapy [3,4].
Foster® (Chiesi Farmaceutici S.p.A., Parma, Italy) is an extraﬁne
formulation ﬁxed-dose combination (FDC) of the ICS beclometa-
sone dipropionate (BDP) and the LABA formoterol fumarate (FF)
delivered via a hydroﬂuoroalkane (HFA) pressurised metered dose
inhaler (pMDI). A 48-week study in COPD patients showed that
BDP/FF was superior to FF monotherapy in terms of the rate of
exacerbations, lung function and health-related quality of life [4].
Other studies have shown similar clinical beneﬁts with BDP/FF
compared to other ICS/LABA FDC commonly used in clinical prac-
tice, namely ﬂuticasone propionate/salmeterol and budesonide/
formoterol [5,6].
A triple therapy regimen of LABA, LAMA and ICS is a recognised
treatment strategy for COPD patients who have a high burden of
symptoms and who are at increased risk of exacerbations; these
patients are categorised as GOLD category D [1]. In clinical practice
it is common for patients with COPD to be ‘stepped up’ frommono-
LAMA or ICS/LABA therapy to such a triple regimen [7], and there is
evidence that stepping up treatment in this manner provides sig-
niﬁcant and clinically important patient beneﬁts such as improved
symptoms and reduced exacerbation rates [8,9].
An extraﬁne formulation of the LAMA glycopyrronium bromide
(GB) is in clinical development to be combined with BDP/FF in a
single inhaler (a ‘ﬁxed triple’) for the management of COPD. The
aim of this study was to determine the dose-response effects of GB
in COPD patients on background BDP/FF treatment. An important
aspect of the study design was that we included only patients who
were being treated with ICS/LABA FDCs on entry to the study.
2. Materials and methods
2.1. Participants
This was a multicentre, double-blind, randomised, active- and
placebo-controlled, 4-way crossover study, that recruited males
and females from 40 to 80 years of age, who had a diagnosis of
COPD according to the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) strategy document. To be eligible, patients
were required to have a post-bronchodilator forced expiratory
volume in 1 s (FEV1) to forced vital capacity (FVC) ratio <0.7, a post-
bronchodilator FEV1 between 30 and 60% of the predicted value,
and an increase in FEV1 of at least 60 mL at 30 min after inhalation
of 80 mg ipratropium. All patients were to be receiving an ICS/LABA
combination on entry to the study (ICS/LABA plus tiotropium was
acceptable providing this was taken for no longer than 1 month
prior to study entry; tiotropiumwas not to be taken from 24 h prior
to screening and for the duration of the study). Current or ex-
smokers with a smoking history of at least 10 pack-years were
eligible.
The key exclusion criteriawere: a diagnosis of asthma, or history
of allergic rhinitis or atopy; hospitalisation for COPD or pneumonia
within 3 months prior to screening; a COPD exacerbation requiring
systemic steroids and/or antibiotics in the 4 weeks prior to
screening, or during the run-in period; and hypersensitivity to any
of the study drugs or excipients. Patients were also excluded if they
had clinically signiﬁcant abnormal electrocardiograms (ECG), QTc
(Fridericia's formula) > 450 ms for males or >470 ms for females,
clinically signiﬁcant laboratory abnormalities that could impact the
feasibility of the results, or unstable concurrent disease, or required
long-term (at least 12 h daily) oxygen therapy for chronichypoxaemia.
2.2. Trial design
The studywas conducted at amixture of primary, secondary and
tertiary care, and specialised research institutions. It comprised
four 7-day treatment periods with 7-day washout periods between
treatments (Fig. 1). At the screening visit (Visit 1), inclusion and
exclusion criteria were checked, with spirometry assessed pre- and
30-min post ipratropium 80 mg. There was a 4-week run-in period
between Visits 1 and 2, during which all patients received BDP/FF
100/6 mg, two inhalations (i.e., 200/12 mg) twice daily (BID) via
pressurisedmetered dose inhaler (pMDI). At the baseline visit (Visit
2), after conﬁrming eligibility, patients were randomised equally to
one of four treatment sequences. On Day 1 of each treatment period
(Visits 2, 4, 6 and 8), pre- and post-dose spirometry (FEV1, FVC and
inspiratory capacity [IC]) were measured (at 45, 10, 15, 30 and
45 min, and 1, 2, 4, 6, 8, 10 and 12 h, and 12 h 30 min). The evening
dose of study medication was inhaled after the 12 h 30 min
spirometry assessments. On Day 7 of each treatment period (Visits
3, 5, 7 and 9), pre- and post-dose spirometry (FEV1, FVC and IC)
were measured at the same timepoints as Day 1, and also at 14 h,
23 h 30 min and 24 h. As with the Day 1 visit, the evening dose of
study medication was inhaled after the 12 h 30 min spirometry
assessments, and so the 14 h, 23 h 30 min and 24 h spirometry
assessments were therefore effectively obtained at 1 h 30 min, 11 h
and 11 h 30 min after the evening dose of medication.
The study was conducted in accordance with the provisions of
the Declaration of Helsinki and Good Clinical Practice guidelines,
and was approved by the Independent Ethics Committees or In-
dependent Review Boards at all sites prior to initiation. All patients
provided written informed consent at a prescreening visit before
any study procedure was performed. There were no amendments
to the protocol.
2.3. Interventions
Over the four treatment periods, patients were to receive GB
12.5, 25 and 50 mg BID (i.e., total daily doses of 25, 50 or 100 mg), and
matching placebo, delivered via HFA pMDI. All patients also
received BDP/FF 200/12 mg BID via HFA pMDI for the duration of the
study (including the run-in, treatment and washout periods).
Patients were randomised to one of four treatment sequences
using a balanced block randomisation scheme generated by Bilcare
Global Clinical Supplies, Phoenixville, PA, USA. Patient numbers
were centrally assigned via interactive response technology (voice
and/or web), with treatment kits corresponding to the treatment
regimen dispensed at the start of each treatment period. All study
site personnel and employees of the sponsor (and their represen-
tatives) were blinded to treatment, as were the patients.
2.4. Outcomes and assessments
The primary objective was to evaluate the effect of GB 12.5, 25
and 50 mg BID (i.e., total daily doses of 25, 50 and 100 mg) plus BDP/
FF compared with BDP/FF alone in terms of FEV1 time-normalised
area under the curve from 0 to 12 h (AUC0e12h) on Day 7. Second-
ary objectives included the evaluation of GB plus BDP/FF compared
with BDP/FF alone in terms of: FEV1 AUC0e12h on Day 1; peak FEV1
and FVC on Days 1 and 7; trough FEV1, FVC and IC at 12 h on Days 1
and 7 (where trough was the mean of the assessments at 12 and
12.5 h post-dose); trough FEV1, FVC and IC assessed on the morning
of Day 8 (the mean of the assessments at 23.5 h and 24 h after the
time of dosing on the morning of Day 7); individual timepoint FEV1,
FVC and IC on Days 1 and 7; and rescue medication use across the
Fig. 1. Study design.
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and average number of times that rescue medication was used).
Safety was assessed in terms of adverse events (AEs) and serious
adverse events (SAEs), together with vital signs in each treatment
period. Treatment compliance was evaluated on the basis of diary
card information recorded daily by patients, calculated as the total
number of administered doses divided by the total number of
scheduled doses times 100.Table 1
Patient baseline demographics and disease characteristics (safety population).
Overall (N ¼ 178)
Male gender, n (%) 119 (66.9)
Race, Caucasian, n (%) 178 (100)
Age, years, mean (SD) 62.7 (7.54)
Body mass index, kg/m2, mean (SD) 27.0 (5.72)
Smoking status, n (%)
Ex-smoker 81 (45.5)
Smoker 97 (54.5)
Pack-years, mean (SD) 46.9 (26.13)
Duration of smoking, years, mean (SD) 40.6 (8.90)
Time since COPD diagnosis, years, mean (SD) 8.3 (6.15)
FEV1, L, mean (SD)a 1.41 (0.335)
FEV1, % predicted, mean (SD)a 48.9 (7.34)
30%e<50%, n (%) 81 (45.5)
50%e<60%, n (%) 95 (53.4)
FEV1 reversibility, %, mean (SD)b 16.4 (12.06)
FEV1 reversibility, mL, mean (SD)b 190 (110)
FEV1/FVC, mean (SD)a 0.45 (0.100)
IC, L, mean (SD)a 2.21 (0.69)
a Post-ipratropium (80 mg).
b Post vs pre-ipratropium (80 mg).2.5. Sample size and statistical methods
A total of 142 evaluable patients would provide 93% power to
detect a mean difference of 0.08 L between each dose of GB plus
BDP/FF versus BDP/FF alone at a two-sided signiﬁcance level of
0.01667, assuming a within-subject SD of 0.172 L. Bonferroni's
adjustment was used to control the family-wise Type I error rate at
0.05 (two sided). Jointly considering the tests at the three dose
levels, the overall study power was 80%. Assuming a non-evaluable
rate of 20%, a total of 180 patients would have needed to be rand-
omised. Anticipating a screen failure rate of 30%, a total of 258
patients were required to be screened. Patients who prematurely
withdrew from the study were not replaced.
The primary efﬁcacy variable, FEV1 AUC0e12h, was calculated
based on actual times using the linear trapezoidal rule. The results
were then analysed using an analysis of covariance (ANCOVA)
model, with treatment, period and patient as ﬁxed effects and
baseline FEV1 (mean of the 45 min and 10 min predose on Day 1
values) as covariate. Adjusted mean differences were calculated,
together with Dunnett's simultaneous 95% conﬁdence intervals
(CIs) and p values.
Secondary FEV1, FVC and IC variables were analysed using a
similar ANCOVA model as used for the primary variable, using
baseline FEV1, FVC or IC, as relevant. Peak FEV1 and FVC values were
the maximum obtained between 15 min and 12.5 h post-dose.
Mean individual timepoint FEV1, FVC and IC were summarised by
treatment. The rescue medication variables were analysed using an
analysis of variance (ANOVA) model, with treatment, period and
patient as ﬁxed effects. AEs and SAEs are presented descriptively.
The intent-to-treat (ITT) population comprised all patients who
received at least one administration of study medication and had at
least one post-baseline efﬁcacy evaluation. The per-protocol (PP)
population, which was used only for the primary efﬁcacy variable,
comprised all patients in the ITT population without any major
protocol deviations. The safety population comprised all patients
who received at least one administration of study medication.3. Results
3.1. Participants
The study started in March 2012, and the last patient completed
in September 2012. The study was conducted at 31 centres (4 pri-
mary care, 17 secondary or tertiary care, and 10 specialist research
institutions): 10 in Germany, 6 in Hungary, 2 in Italy, 5 in Poland, 6
in Russia and 2 in the United Kingdom. Of 255 patients screened,
178 were randomised; the majority of patients (n ¼ 172; 96.6%)
completed the study. Of the 77 patients who were not randomised,
65 did not meet the lung function inclusion criteria. Three patients
(1.7%) prematurely discontinued due to withdrawal of consent, and
3 (1.7%) due to adverse events. Baseline demographics and disease
characteristics are shown in Table 1. Demographic and disease
characteristics of the 77 patients who were not randomised were
similar to the overall randomised population: 42 (64.5%) were
male; mean age 62.2 years; mean FEV1 post-ipratropium 55.6%
(22.0e81.0%); mean reversibility to ipratropium 7.5%.
The majority of patients (n ¼ 174; 97.8%) were receiving ICS/
LABA combination for their COPD on entry to the study; the
remainder (n ¼ 4; 2.2%) were receiving triple therapy. Compliance
to treatment was very high, with a mean of 99.4% of scheduled
doses taken during the treatment periods.
Fig. 3. FEV1 AUC0e12h on Day 1 (ITT population). (Data are adjusted mean and 95% CI;
N values are for the ITT population. *p < 0.001 vs BDP/FF; yp < 0.05 vs GB 12.5 mg BID
plus BDP/FF; zp < 0.05 vs GB 25 mg BID plus BDP/FF).
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The mean FEV1 AUC0e12h on Day 7 was signiﬁcantly higher for
all three GB doses plus BDP/FF compared to BDP/FF alone, with
differences ranging from 87 mL to 112 mL in the ITT population
(Fig. 2), and the difference for the 25 and 50 mg BID doses being
clinically relevant (i.e., 100 mL [10]). The difference between GB
50 mg BID and 12.5 mg BID reached statistical signiﬁcance (25 mL,
p ¼ 0.025); the other comparisons between GB doses were not
statistically signiﬁcant. A similar effect was observed in a post-hoc
analysis of the subgroup with baseline post-bronchodilator FEV1
<50% predicted, with differences between GB plus BDP/FF vs BDP/
FF alone of 85, 86 and 115mL for GB 12.5, 25 and 50 mg, respectively
(p < 0.001 for all GB doses). A further post-hoc analysis was con-
ducted to assess the proportion of ‘responders’, deﬁned as a change
in FEV1 AUC0e12h from baseline to Day 7 of >100 mL. The per-
centage of patients meeting this deﬁnition were: 56.6%, 60.0%, and
65.1% with BDP/FF plus GB 12.5, 25, and 50 mg respectively, and
31.4% with BDP/FF alone.3.3. Secondary efﬁcacy endpoints
3.3.1. FEV1 AUC0e12h on Day 1
The addition of all three GB doses to BDP/FF resulted in statis-
tically signiﬁcant increases in FEV1 AUC0e12h on Day 1 (Fig. 3). The
50 mg BID dose was statistically superior to the 25 and 12.5 mg BID
doses, and the 25 mg BID dose was statistically superior to the
12.5 mg BID dose.3.3.2. Trough FEV1, FVC and IC
Trough FEV1 at 12 h post-dose on Days 1 and 7, and on the
morning of Day 8 (assessed at 24 h after the morning dose on Day 7
e in other words, approximately 11.5 h after the evening dose) are
shown in Fig. 4, with the respective FVC and IC data in
Supplementary Figs. 1 and 2. As with the primary endpoint, the
addition of all three doses of GB was associated with statistically
signiﬁcant improvements compared with BDP/FF alone for trough
FEV1, FVC and IC at all three timepoints, with a trend towards
increased efﬁcacy with increased GB dose. The addition of GB 12.5,
25 and 50 mg BID doses resulted in increases vs BDP/FF in troughFig. 2. Primary endpoint e FEV1 AUC0e12h on Day 7 (ITT population). (DatFEV1 at 12 h post-dose of 49, 92 and 106 mL, respectively, on Day 1
and 79, 91 and 105 mL, respectively, on Day 7. A post-hoc analysis
was conducted to assess the proportion of ‘responders’, deﬁned as a
change in trough FEV1 from baseline to the morning on Day 8 of
>100 mL. The percentage of patients meeting this deﬁnition were:
37.6%, 42.9%, and 43.0% with BDP/FF plus GB 12.5, 25, and 50 mg,
respectively and 19.8% with BDP/FF alone.
3.3.3. Peak FEV1 and FVC
The peak values for FEV1 and FVC in the three GB plus BDP/FF
groups were signiﬁcantly higher (p 0.001) than the BDP/FF group
on both Day 1 and Day 7. On Day 7, the differences in peak FEV1
between BDP/FF and GB were 83mL for the 12.5 mg BID dose, 90 mL
for the 25 mg BID dose and 101 mL for the 50 mg BID dose.
3.3.4. Other secondary efﬁcacy endpoint data
FEV1 reached a peak at 2 h post-dosewith all treatments on both
Day 1 (data not shown) and Day 7 (Fig. 5), with a greater
improvement observed at all timepoints in the three GB plus BDP/
FF groups compared with the BDP/FF alone group. Similar resultsa are adjusted mean and 95% CI; N values are for the ITT population).
Fig. 4. Trough FEV1 at 12 h post-dose on Days 1 and 7, and on Day 8 (ITT population). (Data are adjusted mean and 95% CI; N values are for the ITT population. *p < 0.001 vs BDP/FF;
yp < 0.05 vs GB 12.5 mg BID plus BDP/FF). Note: This ﬁgure shows trough FEV1 assessed at 12 h after the morning dose on Days 1 and 7, and assessed on the morning of Day 8 at 24 h
after the morning dose on Day 7 e in other words, approximately 11.5 h after the Day 7 evening dose.
Fig. 5. Individual timepoint FEV1 on Day 7 (ITT population). (Data are mean; N values are for the ITT population).
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similar across groups, with no statistically signiﬁcant differences in
any of the endpoints.
3.4. Safety results
Overall, 70 treatment-emergent AEs were reported in 47 pa-
tients, and more frequently in the BDP/FF group than any of the GB
plus BDP/FF groups (Table 2). The treatment-emergent AEs occur-
ring in more than one patient in any treatment group were naso-
pharyngitis, oral herpes, headache, fatigue, and increased blood
bilirubin. The majority of AEs were mild in severity; only four were
classiﬁed as severe. There were four serious AEs (reported in threepatients), none of which resulted in death, none reported by more
than one patient, and none considered related to study drug. These
serious AEs were: intestinal abscess, reported in a patient during
treatment with GB 12.5 mg; bladder transitional cell carcinoma
stage II, reported in a patient during treatment with GB 25 mg; and
enteritis infectious and acute prerenal failure, both of which were
reported in a patient during treatment with GB 50 mg. There were
no noticeable changes in vital signs from Day 1 to Day 7 in any
treatment group.
4. Discussion
This study demonstrated that 7 days treatment with an
Table 2
Number of patients with treatment emergent AEs, SAEs, and most common AEs (occurring in at least 2 patients in any treatment group) (safety population).
Patients, n (%) GB 12.5 mg BID þ BDP/FF
(N ¼ 175)
GB 25 mg BID þ BDP/FF
(N ¼ 175)
GB 50 mg BID þ BDP/FF
(N ¼ 175)
BDP/FF
(N ¼ 172)
Overall
(N ¼ 178)
Any treatment-emergent AE 13 (7.4) 10 (5.7) 14 (8.0) 19 (11.0) 47 (26.4)
Nasopharyngitis 0 0 0 2 (1.2) 2 (1.1)
Oral herpes 2 (1.1) 0 0 0 2 (1.1)
Headache 1 (0.6) 0 2 (1.1) 4 (2.3) 7 (3.9)
Fatigue 0 0 2 (1.1) 1 (0.6) 3 (1.7)
Blood bilirubin increased 0 0 0 3 (1.7) 3 (1.7)
Patients with study drug permanently discontinued due to a
treatment-emergent AE
1 (0.6) 1 (0.6) 1 (0.6) 0 3 (1.7)
Any treatment-emergent SAE 1 (0.6) 1 (0.6) 1 (0.6) 0 3 (1.7)
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dependent improvements in lung function. The primary endpoint
analysis of FEV1 AUC0e12h on Day 7 showed that both 25 and 50 mg
BID doses resulted in lung function improvements 100 mL. An
FEV1 change of 100 mL has been described as one that patients
can perceive, and so is considered clinically relevant [10]. Although
strictly speaking this refers to a single FEV1 assessment (rather than
the averaged value that the AUC represents), we believe that this
suggests that the 25 mg BID dose may meet the criteria for the
minimally effective dose. The results for the other spirometry
endpoints were consistent with the primary endpoint, in that all
three GB doses resulted in statistically signiﬁcant improvements in
lung function when added to BDP/FF, with evidence of a dose-
response.
The primary and secondary endpoint data for FEV1 AUC0e12h
and trough values on Days 1 and 7 (Figs. 2e4) all show a numerical
dose-response relationship, with 12.5 mg BID having the lowest
numerical effect and 50 mg BID having the highest numerical effect.
The differences between 12.5 and 25 mg BID were not consistently
statistically signiﬁcant, but it should be noted that the study was
not sufﬁciently powered or designed to detect smaller differences
between doses, but was powered to detect an 80 mL improvement
versus BDP/FF alone. For the primary endpoint (FEV1 AUC0e12h on
Day 7),12.5 mg BID failed tomeet the 100mL threshold [10]. Overall,
therefore, the results presented here suggest that the effects of
12.5 mg BID fall below the clinically relevant threshold, while higher
doses are more likely to be effective in clinical practice.
The primary endpoint results of the current study are consistent
with those of a previous crossover study in COPD patients, which
compared the effects of ‘triple therapy’ in the form of ﬂuticasone
propionate/salmeterol 500/50 mg BID plus tiotropium 18 mg once
daily on lung function with that of ﬂuticasone propionate/salme-
terol or tiotropium bromide [11]. After 14 days, the difference in
FEV1 between the triple therapy and ﬂuticasone propionate/sal-
meterol was 90 mL at 2 h post-dose and 100 mL at 4 h (both
p < 0.05), with a difference in predose (trough) FEV1 of 110 mL. The
results are also consistent with a 12-week study inwhich the LAMA
umeclidiniumwas added to the ICS/LABA FDC ﬂuticasone fumarate/
vilanterol [12]. At Day 85 trough FEV1 was increased by
122e124mL by the addition of umeclidinium 62.5 mg to ﬂuticasone
fumarate/vilanterol 100/25 mg.
This study examined the beneﬁts of inhaled GB in the context of
triple therapy compared with dual ICS/LABA therapy, with patients
being ‘stepped up’ from ICS/LABA (in the run-in to each treatment
period) to ICS/LABA plus LAMA. This also addresses one of the
shortcomings of the designs of typical COPD clinical trialse namely
the recruitment of heterogeneous patient populations into clinical
trials. For example, many large trials of ICS have enrolled patients
using ICS and those not using ICS [13,14]. Furthermore, in these
other trials ICS were stopped during the run in, before random-
isation to active treatment including ICS or placebo. All of thepatients recruited into our study were taking ICS/LABA before
screening (97.8% were receiving ICS/LABA on entry, with the
remaining 2.2% receiving ICS/LABA/LAMA), and continued on a
standardised ICS/LABA regimen during the study so removing such
heterogeneity, making the evaluation of LAMA efﬁcacy more clin-
ically representative and the potential confounding of the conclu-
sions drawn.
ICS/LABA treatment is one of the two most common routes to
triple inhaled therapye the other being the addition of an ICS/LABA
combination to LAMA. In this context, we believe that the recruited
population is representative of those who could receive triple
therapy in real life. However, this was a short-term crossover study
designed to evaluate the dose-response to GB, so patients were not
required to be symptomatic or to have a history of frequent exac-
erbations e either of which would be the rationale for increasing
therapy from ICS/LABA to triple inhaled therapy in real life.
A characteristic feature of COPD is hyperinﬂation, which is due
to air trapping that results from expiratory ﬂow limitation [15].
Hyperinﬂation can occur during exercise (dynamic hyperinﬂation)
or at rest, and, together with peripheral muscle weakness, can
result in activity limitation (or avoidance) that impacts overall
quality of life [15]. Long-acting bronchodilators improve lung
emptying, thereby reducing hyperinﬂation, with a combination of a
LAMA and a LABA having been shown to be more effective in this
regard than bronchodilator monotherapy [16]. In this context, the
two volume measures included in this study (FVC and IC) provide
further support for the beneﬁt of adding a LAMA to ICS/LABA
therapy.
The crossover design of the study meant that washout periods
were required between the treatment periods (during which pa-
tients continued only with BDP/FF). The duration of these washout
periods was determined by the plasma elimination half-life of GB;
we observed similar baseline (pre-treatment) mean FEV1 values at
the start of each treatment period, conﬁrming a lack of period or
carry-over effect. The duration of treatment (7 days) was consid-
ered sufﬁcient for the lung function parameters to be assessed
accurately. This study design is not appropriate, however, for the
assessment of symptoms which require a longer treatment period.
Since this study set out to investigate dose-response from a
relatively small sample size, we excluded patients with limited or
no bronchial reversibility to improve the chances of observing a
dose-response. Such inclusion criteria are common in short term
crossover studies of bronchodilators in COPD [17,18]. The potential
criticism of using a reversibility threshold for inclusion is that the
study is biased towards reversible COPD patients. This would
certainly be the casewhen using a threshold such as 200mL.We set
a lower (arbitrary) value of 60 mL in order to avoid this issue, but at
the same time also avoiding recruiting patients with very low
(<60 mL) bronchodilator responses where it would be difﬁcult to
study dose response effects.
Although another dry-powder formulation of GB is approved for
D. Singh et al. / Respiratory Medicine 114 (2016) 84e9090once-daily dosing (at a dose of 50 mg once daily), it has been shown
that GB can be administered twice daily [19] e the dosing regimen
used for the formulation in the current study. Given the twice daily
dosing regimen of BDP/FF, in the same device as used for GB in the
current study, a logical future development is the co-formulation of
BDP/FF and GB in the same inhaler. This would translate into ad-
vantages to patients, who, in order to receive LABA plus LAMA plus
ICS therapy, currently have to use two different inhaler devices.
Furthermore, although this study is not long enough to draw ﬁrm
conclusions on the safety proﬁle of GB, the relatively low number of
AEs and the lack of relationship between AE incidence and GB dose
is reassuring.
In conclusion, for patients already on BDP/FF, this study shows
the potential beneﬁts on lung function of stepping up to triple
therapy through the addition of extraﬁne GB delivered via pMDI
administered twice daily. The results suggest that GB 25 mg BIDmay
meet the criteria for the minimally effective dose, although addi-
tional studies are required to conﬁrm this. The symptomatic and
longer-term clinical beneﬁts of this approach are being investigated
in long-term studies.
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